Study finds biopharmaceutical innovation is responsible for 35% of the increase in life expectancy from 1990 to 2015
By Gabby Migliara | October 21, 2020
Medicines are responsible for more than a third of the improvement in life expectancy from 1990 to 2015, according to a recent study published in Health Affairs. This underscores the crucial role...
Read More
New report explores setbacks that bring future cancer success stories
By Giovanni Caforio, M.D. | July 16, 2020
Conversations and healthy debate about issues facing the biopharmaceutical industry and the health care system are critical to addressing the important work we do for patients. The Catalyst...
Read More
Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic
By Guest Contributor | June 24, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Cancer medicines cost twice as much at hospitals, study finds
By Katie Koziara | January 21, 2020
Cancer medicines cost nearly twice as much in hospital outpatient facilities than in physician offices in the commercial market, according to a new study from the Employee Benefit Research...
Read More
ICYMI: Cancer death rate declines at record levels thanks to innovative medicines
By Andrew Powaleny | January 9, 2020
Each year, the American Cancer Society estimates the number of new cancer cases and deaths that will occur in the United States. For nearly 30 years, the trend towards fewer cancer deaths has been...
Read More
Saving kids and dogs from shared cancers
By Guest Contributor | September 17, 2018
Ulrike Szalay is the Founder and Executive Director of Canines-N-Kids Foundation Did you know? Dogs and children spontaneously develop a number of similar cancers. In fact, cancer is the leading...
Read More
New analysis shows that more medicines worldwide are available to U.S. patients
By Kevin Haninger | June 5, 2018
In the past year, we have seen revolutionary new treatments become available to patients in the United States for cancer and other debilitating diseases. A new analysis puts in perspective the...
Read More
New analysis shows that HTA organizations may frequently restrict access to cancer treatments
By Randy Burkholder | June 1, 2018
In health care, who should decide value? In many industrialized countries with single-payer health systems, the answer is “the government.” A new analysis by Avalere illustrates the negative...
Read More
New report and resources put cancer in context, showing more than 1,100 medicines and vaccines in development
By Andrew Powaleny | May 30, 2018
In the not too distant past, chemotherapy and radiation were once the only treatments for what remains the second leading cause of death in the United States – cancer. Although the death rates of...
Read More
Spending on medicines grew less than one percent in 2017
By Holly Campbell | April 19, 2018
Last year, a record number of new treatments and cures that are transforming care for patients fighting debilitating diseases like cancer, hepatitis C, high cholesterol and more were approved by...
Read More
Medicare Monday (100)
340B Spotlight (45)
Cost & Consequence (0)
